358 related articles for article (PubMed ID: 24885794)
21. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Zhang X; Chen X; Lin J; Lwin T; Wright G; Moscinski LC; Dalton WS; Seto E; Wright K; Sotomayor E; Tao J
Oncogene; 2012 Jun; 31(24):3002-3008. PubMed ID: 22002311
[TBL] [Abstract][Full Text] [Related]
22. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
[TBL] [Abstract][Full Text] [Related]
23. A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
Esperanza-Cebollada E; Gómez-González S; Perez-Jaume S; Vega-García N; Vicente-Garcés C; Richarte-Franqués M; Rives S; Català A; Torrebadell M; Camós M
Br J Haematol; 2023 Jul; 202(1):96-110. PubMed ID: 36951259
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
25. Protein tyrosine phosphatases receptor type D is a potential tumour suppressor gene inactivated by deoxyribonucleic acid methylation in paediatric acute myeloid leukaemia.
Song L; Jiang W; Liu W; Ji JH; Shi TF; Zhang J; Xia CQ
Acta Paediatr; 2016 Mar; 105(3):e132-41. PubMed ID: 26607758
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Miyamura T; Moritake H; Nakayama H; Tanaka S; Tomizawa D; Shiba N; Saito AM; Tawa A; Shimada A; Iwamoto S; Hayashi Y; Koike T; Horibe K; Manabe A; Mizutani S; Taga T; Adachi S
Br J Haematol; 2019 Apr; 185(2):284-288. PubMed ID: 30784060
[TBL] [Abstract][Full Text] [Related]
27. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.
Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S
Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968
[No Abstract] [Full Text] [Related]
28. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
29. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
30. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
31. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
Vandewalle V; Essaghir A; Bollaert E; Lenglez S; Graux C; Schoemans H; Saussoy P; Michaux L; Valk PJM; Demoulin JB; Havelange V
J Cell Mol Med; 2021 Jan; 25(1):575-585. PubMed ID: 33270982
[TBL] [Abstract][Full Text] [Related]
32. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
[TBL] [Abstract][Full Text] [Related]
33. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21).
Yin JY; Tang Q; Qian W; Qian J; Lin J; Wen XM; Zhou JD; Zhang YY; Zhu XW; Deng ZQ
Int J Clin Exp Pathol; 2014; 7(11):8032-8. PubMed ID: 25550847
[TBL] [Abstract][Full Text] [Related]
35. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies.
Chim CS; Wong KY; Leung CY; Chung LP; Hui PK; Chan SY; Yu L
J Cell Mol Med; 2011 Dec; 15(12):2760-7. PubMed ID: 21323860
[TBL] [Abstract][Full Text] [Related]
37. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.
Jiang X; Hu C; Arnovitz S; Bugno J; Yu M; Zuo Z; Chen P; Huang H; Ulrich B; Gurbuxani S; Weng H; Strong J; Wang Y; Li Y; Salat J; Li S; Elkahloun AG; Yang Y; Neilly MB; Larson RA; Le Beau MM; Herold T; Bohlander SK; Liu PP; Zhang J; Li Z; He C; Jin J; Hong S; Chen J
Nat Commun; 2016 Apr; 7():11452. PubMed ID: 27116251
[TBL] [Abstract][Full Text] [Related]
38. Alleviating the progression of acute myeloid leukemia (AML) by sulforaphane through controlling miR-155 levels.
Koolivand M; Ansari M; Piroozian F; Moein S; MalekZadeh K
Mol Biol Rep; 2018 Dec; 45(6):2491-2499. PubMed ID: 30350234
[TBL] [Abstract][Full Text] [Related]
39. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
[TBL] [Abstract][Full Text] [Related]
40. miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers.
Cheng YC; Fan Z; Liang C; Peng CJ; Li Y; Wang LN; Luo JS; Zhang XL; Liu Y; Zhang LD
Technol Cancer Res Treat; 2024; 23():15330338241248576. PubMed ID: 38693824
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
